As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Evommune, Inc. The largest reported stake is LSP 7 Cooperatieve U.A.'s, at 14.7%. 9 filings are on record since November 14, 2025 (Schedule 13D/A, February 19, 2026).
Sell to companies like Evommune, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: T. Rowe Price Associates, Inc. · Sole voting: 1,940,939 · Shared voting: 0 · Sole dispositive: 1,940,939 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Andera Partners · Sole voting: 0 · Shared voting: 1,391,990 · Sole dispositive: 0 · Shared dispositive: 1,391,990 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Point72 Asset Management, L.P. · Sole voting: 0 · Shared voting: 1,910,489 · Sole dispositive: 0 · Shared dispositive: 1,910,489 · SCHEDULE 13G, 2026-07-16
- · Reporting person: LSP 7 Cooperatieve U.A. · Sole voting: 0 · Shared voting: 5,288,313 · Sole dispositive: 0 · Shared dispositive: 5,288,313 · SCHEDULE 13D/A, 2026-02-19
- · Holder: RA Capital Management, L.P. · Percent: 9.7% · SCHEDULE 13D/A
Evommune, Inc. has 9 Schedule 13D or 13G filings on record since 2025-11-14. 5 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. | 14.7% | 5,288,313 | SCHEDULE 13D/A, 2026-02-19 | 2026-02-12 |
| Nan Fung Group Holdings Limited | 10.9% | 3,435,599 | SCHEDULE 13G, 2026-02-13 | 2025-12-31 |
| RA Capital Management, L.P. | 9.7% | 3,494,638 | SCHEDULE 13D/A, 2026-02-17 | 2026-02-12 |
| T. Rowe Price Associates, Inc. | 5.4% | 1,940,939 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Point72 Asset Management, L.P. | 5.3% | 1,910,489 | SCHEDULE 13G, 2026-07-16 | 2026-07-15 |
| Andera Partners | 3.9% | 1,391,990 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Evommune, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Evommune, Inc. and the records around it.
Evommune, Inc. elsewhere on the record
Companies that share a holder
- Andera Partners also filed stake reports on 2 other companies: Inventiva S.A. (Oct 2026), MINERALYS THERAPEUTICS, INC. (Aug 2025)
- Nan Fung Group Holdings Limited also filed stake reports on 2 other companies: Bolt Biotherapeutics, Inc. (Feb 2026), Oculis Holding AG (Nov 2025)
- LSP 7 Cooperatieve U.A. also filed stake reports on 3 other companies: Electra Therapeutics, Inc. (Sep 2026), Oculis Holding AG (Apr 2026), AgomAb Therapeutics NV (Feb 2026)
Watch Evommune, Inc.
Get an email when Evommune, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Evommune, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Evommune, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evommune, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. | 0 | 5,288,313 | 0 | 5,288,313 | SCHEDULE 13D/A, 2026-02-19 |
| LSP 7 Management B.V. | 0 | 5,288,313 | 0 | 5,288,313 | SCHEDULE 13D/A, 2026-02-19 |
| T. Rowe Price Associates, Inc. | 1,940,939 | 0 | 1,940,939 | 0 | SCHEDULE 13G, 2026-08-14 |
| Point72 Asset Management, L.P. | 0 | 1,910,489 | 0 | 1,910,489 | SCHEDULE 13G, 2026-07-16 |
| Point72 Capital Advisors, Inc. | 0 | 1,910,489 | 0 | 1,910,489 | SCHEDULE 13G, 2026-07-16 |
| Steven A. Cohen | 0 | 1,910,489 | 0 | 1,910,489 | SCHEDULE 13G, 2026-07-16 |
| Andera Partners | 0 | 1,391,990 | 0 | 1,391,990 | SCHEDULE 13G/A, 2026-08-14 |
| BioDiscovery 6 FPCI | 0 | 1,391,990 | 0 | 1,391,990 | SCHEDULE 13G/A, 2026-08-14 |
| Stephane Bergez | 0 | 1,391,990 | 0 | 1,391,990 | SCHEDULE 13G/A, 2026-08-14 |
| Francois Xavier Mauron | 0 | 1,391,990 | 0 | 1,391,990 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Evommune, Inc. by CUSIP 30054Y107 and gives its principal executive office as 1891 PAGE MILL RD, PALO ALTO, CA 94304 (SCHEDULE 13G, 2026-08-14).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.Andera Partners, SCHEDULE 13G/A, 2026-08-14
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby amended and supplemented as follows: February 2026 Securities Purchase Agreement On February 12, 2026, the Issuer entered into a securities purchase agreement (the "February 2026 Securities Purchase Agreement") with certain institutional accredited investors (the "February 2026 PIPE Investors"), including LSP 7, pursuant to which the Issuer agreed to issue and sell to the February 2026 PIPE Investors in a private placement (the "February 2026 Private Placement") an aggregate of 4,494,279 shares of Common Stock (the "Shares") at a price of $27.88 per share.LSP 7 Cooperatieve U.A., SCHEDULE 13D/A, 2026-02-19
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | LSP 7 Cooperatieve U.A. | 15.7% | SCHEDULE 13D |
| 2025-11-17 | RA Capital Management, L.P. | 11% | SCHEDULE 13D |
| 2025-11-17 | Andera Partners | 6% | SCHEDULE 13G |
| 2026-02-13 | Nan Fung Group Holdings Limited | 10.9% | SCHEDULE 13G |
| 2026-02-17 | RA Capital Management, L.P. | 9.7% | SCHEDULE 13D/A |
| 2026-02-19 | LSP 7 Cooperatieve U.A. | 14.7% | SCHEDULE 13D/A |
| 2026-07-16 | Point72 Asset Management, L.P. | 5.3% | SCHEDULE 13G |
| 2026-08-14 | T. Rowe Price Associates, Inc. | 5.4% | SCHEDULE 13G |
| 2026-08-14 | Andera Partners | 3.9% | SCHEDULE 13G/A |
Questions about who owns Evommune, Inc.
Who owns Evommune, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Evommune, Inc.: LSP 7 Cooperatieve U.A. (14.7%, Schedule 13D/A, filed 2026-02-19), Nan Fung Group Holdings Limited (10.9%, Schedule 13G, filed 2026-02-13), RA Capital Management, L.P. (9.7%, Schedule 13D/A, filed 2026-02-17), T. Rowe Price Associates, Inc. (5.4%, Schedule 13G, filed 2026-08-14) and Point72 Asset Management, L.P. (5.3%, Schedule 13G, filed 2026-07-16).
Who are the largest shareholders of Evommune, Inc.?
By the share each holder's latest filing reports, the largest holders of Evommune, Inc. on this page are LSP 7 Cooperatieve U.A. (14.7%), Nan Fung Group Holdings Limited (10.9%) and RA Capital Management, L.P. (9.7%).
When did LSP 7 Cooperatieve U.A. buy into Evommune, Inc.?
The filings give report dates, not purchase dates. The earliest filing from LSP 7 Cooperatieve U.A. on this page is the Schedule 13D, filed 2025-11-14, reporting 15.7%; its latest, Schedule 13D/A filed 2026-02-19, reports 14.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Evommune, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.